Davenport & Co’s Cognition Therapeutics CGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.08M Sell
4,248,410
-11,101
-0.3% -$11.2K 0.02% 420
2026
Q2
$4.9M Buy
4,259,511
+1,366,703
+47% +$1.62M 0.02% 374
2026
Q1
$2.2M Buy
2,892,808
+20,972
+0.7% +$24.4K 0.01% 506
2025
Q4
$3.88M Buy
2,871,836
+182,500
+7% +$296K 0.02% 395
2025
Q3
$3.63M Buy
+2,689,336
New +$3.67M 0.02% 404

Other funds holding CGTX

Davenport & Co's CGTX Position: Q3 2026 in Review

Davenport & Co reduced its Cognition Therapeutics (CGTX) stake by 0.26% in Q3 2026, selling an estimated $11.2K and leaving 4,248,410 shares worth $4.08M. The position accounts for 0.02% of the portfolio, ranked #420.

Davenport & Co first reported a position in CGTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $4.9M in Q2 2026. 78 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.

  • Davenport & Co held 4,248,410 shares of Cognition Therapeutics worth $4.08M as of Q3 2026.
  • Davenport & Co sold 11,101 Cognition Therapeutics shares in Q3 2026, an estimated $11.2K.
  • Cognition Therapeutics made up 0.02% of Davenport & Co's portfolio in Q3 2026, its #420 holding.
  • Davenport & Co first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Davenport & Co's Cognition Therapeutics position peaked at $4.9M in Q2 2026.
  • 78 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.

Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.